Riley Sanders, MD
Ophthalmology · Little Rock, ARNPI 1790147155
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 45 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 11 manufacturers, the largest accounting for just 22.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $473, 3.9 times the $123 reported in 2022.
Across 45 payments — averaging $26.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$269
- Regeneron Healthcare Solutions, Inc.$217
- AbbVie$151
- Apellis Pharmaceuticals, Inc.$151
- Astellas Pharma US Inc$112
- Alimera Sciences, Inc.$111
- plus $168 from 5 others
What the payments were for
- Food & beverage$1,180100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 7 | $269 |
| Regeneron Healthcare Solutions, Inc. | 9 | $217 |
| AbbVie | 6 | $151 |
| Apellis Pharmaceuticals, Inc. | 6 | $151 |
| Astellas Pharma US Inc | 5 | $112 |
| Alimera Sciences, Inc. | 5 | $111 |
| ANI Pharmaceuticals, Inc. | 2 | $46 |
| Genentech, Inc. | 2 | $37 |
| Harrow Eye, LLC | 1 | $37 |
| Astellas Pharma Global Development | 1 | $26 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- VABYSMO$123
How this compares
$1,180 in reported general payments places this provider in the 60th percentile of 125 ophthalmology providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 127 | $4,931 |
| Ketorolac Tromethamine | 79 | $1,918 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 29 | $299 |
| Latanoprost | 15 | $270 |
| Timolol Maleate | 39 | $227 |
| Brimonidine Tartrate | 31 | $97 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Little Rock
- Jennifer DoyleLittle Rock$38K
- Jonathan CascianoLittle Rock$4K
- Christian HesterLittle Rock$4K
- Sami UwaydatLittle Rock$4K
- Daniel KimLittle Rock$2K
- Justin LieblongLittle Rock$2K
- Kent ZocchiLittle Rock$2K
- Lydia LaneLittle Rock$2K
- Richard MorshediLittle Rock$2K
- Susan BlairLittle Rock$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.